Treatment Comparison Tool for Multiple Myeloma and Ovarian Cancer
Find Your Best Treatment Option
Answer a few questions about your situation to see which treatments might be most appropriate for you.
When you're facing multiple myeloma or ovarian cancer, the choice of chemotherapy isn't just about effectiveness-it's about what your body can handle, what your life looks like on treatment, and what options are still open if the first one stops working. Alkeran, the brand name for melphalan, has been a backbone of treatment for decades. But it’s not the only option anymore. And knowing what else is out there could mean the difference between managing side effects and losing quality of life.
What Alkeran (Melphalan) Actually Does
Melphalan is an alkylating agent. That means it damages the DNA inside cancer cells so they can’t multiply. It’s been used since the 1960s, and it still works-especially for multiple myeloma and some types of ovarian cancer. Doctors often use it before a stem cell transplant to wipe out as many cancer cells as possible. In ovarian cancer, it’s usually reserved for cases that didn’t respond to first-line drugs like carboplatin or paclitaxel.
It comes in two forms: oral tablets and intravenous infusion. The oral version is easier to take at home, but absorption can be unpredictable. The IV version gives more control over dosage, but you need to go to a clinic. Both can cause serious side effects: low blood counts, nausea, hair loss, and a higher risk of infection. Long-term use can also raise the chance of developing secondary cancers like leukemia.
Why People Look for Alternatives
Many patients stop using Alkeran not because it stopped working, but because the side effects became too much. Older adults, people with kidney problems, or those who’ve had multiple rounds of chemo often can’t tolerate it anymore. Others are looking for options that don’t require frequent hospital visits. And some want drugs with newer mechanisms-ones that target cancer more precisely instead of attacking all fast-dividing cells.
Here’s what’s changed since Alkeran became standard: newer drugs have been approved, combination therapies have improved, and personalized medicine is now part of treatment planning. You don’t have to stick with Alkeran if it’s not working for you.
Key Alternatives to Alkeran
There are several drugs that doctors now consider before or instead of melphalan. The best one for you depends on your cancer type, how far it’s spread, your age, kidney function, and whether you’ve had prior treatments.
1. Bortezomib (Velcade)
Bortezomib is a proteasome inhibitor. Instead of damaging DNA, it blocks the cell’s waste disposal system, causing cancer cells to build up toxic proteins and die. It’s now a first-line treatment for multiple myeloma, often used with dexamethasone and lenalidomide.
Compared to Alkeran, bortezomib has fewer issues with bone marrow suppression. But it can cause nerve pain (peripheral neuropathy), low blood pressure, and digestive problems. It’s given as an injection, either under the skin or into a vein, usually once or twice a week.
2. Lenalidomide (Revlimid)
Lenalidomide is an immunomodulatory drug. It doesn’t kill cancer cells directly-it wakes up your immune system to find them and cuts off the blood supply tumors need to grow. It’s taken as a daily pill, which makes it much easier than IV chemo.
Studies show that combining lenalidomide with dexamethasone works just as well as Alkeran-based regimens for newly diagnosed multiple myeloma, with fewer severe infections and less need for blood transfusions. It’s also used after transplant to keep the cancer from coming back.
Downsides? It can cause low white blood cell counts, fatigue, and increases the risk of blood clots. You need regular blood tests and must avoid pregnancy-this drug causes severe birth defects.
3. Carfilzomib (Kyprolis)
Like bortezomib, carfilzomib is a proteasome inhibitor-but it’s stronger and works differently. It’s often used when bortezomib stops working or causes too much nerve pain. It’s given as an IV infusion, usually twice a week.
Compared to Alkeran, carfilzomib causes less bone marrow damage and is more effective in relapsed cases. But it can stress the heart and kidneys. Patients need close monitoring for high blood pressure and fluid retention.
4. Cyclophosphamide (Cytoxan)
Cyclophosphamide is another alkylating agent, similar to melphalan but with a different side effect profile. It’s often used in combination with dexamethasone for multiple myeloma, especially in patients who can’t tolerate high-dose melphalan before transplant.
It’s cheaper than many newer drugs and works well in combination. But it can cause bladder irritation and increases the risk of hemorrhagic cystitis. Patients usually take it with mesna to protect the bladder.
5. Doxorubicin (Adriamycin)
Doxorubicin is a classic chemotherapy drug used in ovarian cancer and sometimes in multiple myeloma when other options fail. It’s given as an IV infusion and works by interfering with DNA replication.
It’s more toxic to the heart than Alkeran, so it’s not used long-term. But in combination with bortezomib or dexamethasone, it can be effective in aggressive cases. Hair loss and nausea are common, but it doesn’t suppress bone marrow as badly as melphalan in some patients.
Comparison Table: Alkeran vs. Top Alternatives
| Drug | Class | Administration | Common Side Effects | Best For | Limitations |
|---|---|---|---|---|---|
| Alkeran (Melphalan) An alkylating agent used for multiple myeloma and ovarian cancer, often before stem cell transplant | Alkylating agent | Oral or IV | Low blood counts, nausea, hair loss, infection risk | High-dose conditioning before transplant; relapsed ovarian cancer | High toxicity; risk of secondary leukemia |
| Bortezomib (Velcade) Proteasome inhibitor that blocks cancer cell waste processing | Proteasome inhibitor | IV or subcutaneous | Nerve pain, low blood pressure, diarrhea | First-line multiple myeloma; patients needing outpatient treatment | Peripheral neuropathy; requires frequent clinic visits |
| Lenalidomide (Revlimid) Immunomodulatory drug that enhances immune response against cancer | Immunomodulator | Oral daily | Low white cells, fatigue, blood clots | Maintenance after transplant; older patients; oral convenience | Teratogenic; requires strict contraception |
| Carfilzomib (Kyprolis) Second-generation proteasome inhibitor for resistant cases | Proteasome inhibitor | IV infusion | High blood pressure, heart strain, fluid retention | Relapsed/refractory multiple myeloma after bortezomib | Requires hospital visits; cardiac monitoring needed |
| Cyclophosphamide (Cytoxan) Alkylating agent with similar use but different toxicity profile | Alkylating agent | Oral or IV | Bladder irritation, nausea, hair loss | Cost-effective option; combination therapy | Bladder damage risk; needs mesna protection |
| Doxorubicin (Adriamycin) Anthracycline antibiotic that disrupts DNA replication | Anthracycline | IV infusion | Heart damage, hair loss, nausea | Aggressive ovarian cancer; salvage therapy | Cardiotoxicity limits long-term use |
When to Switch from Alkeran
You don’t need to wait until Alkeran completely fails to consider alternatives. Many patients switch when:
- Blood counts stay too low for more than two cycles
- Side effects disrupt daily life (e.g., constant nausea, inability to work)
- Kidney function drops below 40% of normal
- The cancer shows signs of becoming resistant (rising M-protein levels)
- You want to avoid frequent hospital visits
Doctors now use genetic testing to predict how well a patient will respond to certain drugs. For example, patients with a deletion in chromosome 17p may respond better to carfilzomib than to melphalan. If your oncologist hasn’t mentioned genetic testing, ask for it.
What About Newer Treatments?
There’s a wave of newer therapies that don’t fit the traditional chemo mold:
- Monoclonal antibodies like daratumumab (Darzalex) and isatuximab (Sarclisa) target specific proteins on myeloma cells. They’re given as infusions and often combined with lenalidomide or bortezomib.
- CAR T-cell therapy like idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) reprograms your own immune cells to hunt cancer. These are used after multiple prior treatments fail.
- CELMoDs like iberdomide and mezigdomide are next-gen versions of lenalidomide with stronger immune effects and are being tested in trials.
These aren’t replacements for Alkeran in early-stage disease-but for patients who’ve tried everything, they’re life-changing. Some are now approved for use after just two prior lines of therapy, not five.
Cost and Accessibility
Alkeran is generic and cheap-often under $100 for a month’s supply. But newer drugs like lenalidomide, bortezomib, and especially CAR T-cell therapy can cost over $300,000 per treatment. Insurance coverage varies widely.
Many drug manufacturers offer patient assistance programs. Hospitals often have financial counselors who can help you apply for grants or co-pay relief. Don’t assume you can’t afford a newer drug-ask. There are often ways to get access.
What to Ask Your Doctor
If you’re on Alkeran or considering it, here are five questions to ask:
- Why are you recommending Alkeran over other options for my specific case?
- Have you checked my genetic profile? Does it suggest a better drug?
- What are the chances this drug will stop working in the next year?
- What are my options if I can’t tolerate the side effects?
- Are there clinical trials I might qualify for?
There’s no shame in asking for a second opinion. Many cancer centers now offer multidisciplinary tumor boards where specialists review complex cases. If your oncologist doesn’t offer this, ask for it.
Final Thoughts
Alkeran isn’t outdated-but it’s no longer the only choice. The goal isn’t just to kill cancer cells. It’s to keep you alive, functional, and as close to normal as possible. If you’re feeling worn down by Alkeran’s side effects, or if your cancer isn’t responding, talk to your oncologist about alternatives. The treatment landscape has changed dramatically in the last 10 years. You deserve to know what else is out there.
Is Alkeran still used today for multiple myeloma?
Yes, Alkeran is still used, especially as a high-dose conditioning treatment before stem cell transplant. But for newly diagnosed patients, it’s often replaced by combinations like lenalidomide-dexamethasone or bortezomib-based regimens because they’re easier to tolerate and have similar or better outcomes.
Can you take Alkeran and lenalidomide together?
Yes, but not usually at the same time. Alkeran is typically given as a high-dose, short-term treatment before transplant. Lenalidomide is used as maintenance therapy afterward, taken daily for months or years. Using them together increases the risk of severe bone marrow suppression, so doctors space them out carefully.
What’s the most common side effect of melphalan?
The most common and serious side effect is myelosuppression-low levels of white blood cells, red blood cells, and platelets. This increases the risk of infection, fatigue, and bleeding. Patients on melphalan need frequent blood tests and sometimes require transfusions or growth factor injections.
Are there oral alternatives to Alkeran?
Yes. Lenalidomide and pomalidomide are oral immunomodulatory drugs commonly used as alternatives. Cyclophosphamide is also available as a pill. These are often preferred for long-term treatment because they don’t require IV access and can be taken at home.
How do I know if a new drug is right for me?
Your oncologist will consider your cancer’s genetic markers, how you responded to past treatments, your age, kidney and heart function, and your lifestyle. Blood tests, imaging, and sometimes biopsies help guide the decision. Don’t rush-take time to understand your options and ask for a second opinion if needed.
If you’re exploring treatment options, keep a journal of your symptoms, side effects, and questions. Bring it to your appointments. The more information you have, the better your care team can tailor your plan. You’re not just a patient-you’re the most important part of your treatment team.